Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer
Ping Zhao, Jian Sun, Xinwei Huang, Xiangwu Zhang, Xin Liu, Rong Liu, Guangshi Du, Wenqiang Gan, Chuanyu Yang, Yiyin Tang, Ceshi Chen, Dewei Jiang
Abstract
. Clinically, tumor samples from breast patients with less response to neoadjuvant chemotherapy showed a high level of EphA2 pS897 expression. In conclusion, KLF5-EphA2 promotes stemness and drug resistance in BLBC and could be a potential target for the treatment of BLBC.
Topics & Concepts
EPH receptor A2Cancer researchMedicineBreast cancerCancerErythropoietin-producing hepatocellular (Eph) receptorReceptor tyrosine kinaseInternal medicineOncologyReceptorAxon Guidance and Neuronal SignalingKruppel-like factors researchHedgehog Signaling Pathway Studies